For example, valproic acid (VPA), a histone deacetylase inhibitor, has been shown to affect osteosarcoma progression by reprogramming cancer cells toward a more stem-like state through epigenetic modifications similar to those mediated by DUX4. Here, DUX4 is linked to osteosarcoma.